Vaccination against T-cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis

Journal of Internal Medicine

Volumn 281, Issue 4, 2017, Pages 383-397

  Gistera A ^a   Hermansson, A ^a   Strodthoff, D ^a   Klement, M L ^a   Hedin, U ^a,b   Fredrikson, G N ^c   Nilsson, J ^c   Hansson, G K ^a   Ketelhuth, D F J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

apolipoprotein B 100; atherosclerosis; epitopes; T cell; vaccination

Indexed keywords

APOLIPOPROTEIN B100; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN; HLA DQA1 ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB3 ANTIGEN; HLA DRB4 ANTIGEN; IMMUNOGLOBULIN G; HLA D ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDARTERECTOMY; EXPERIMENTAL ATHEROSCLEROSIS; HAPLOTYPE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; VACCINATION; VASCULITIS; ANIMAL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; DISEASE MODEL; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; HLA-D ANTIGENS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MACROPHAGES; MICE; MICE, TRANSGENIC; PLAQUE, ATHEROSCLEROTIC; VACCINATION;

EID: 85013116270     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12589     Document Type: Article

References (63)

1. WHO, ed. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization, 2009.
2. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78.
3. Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009; 30: 2838–44.
4. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116: 1832–44.
5. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90: 1138–44.
6. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13: 341–90.
7. Steinbrecher UP, Zhang HF, Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Radic Biol Med 1990; 9: 155–68.
8. Ketelhuth DF, Rios FJ, Wang Y et al. Identification of a danger-associated peptide from apolipoprotein B100 (ApoBDS-1) that triggers innate proatherogenic responses. Circulation 2011; 124: 2433–43, 1–7.
9. Hermansson A, Johansson DK, Ketelhuth DF, Andersson J, Zhou X, Hansson GK. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 2011; 123: 1083–91.
10. Hermansson A, Ketelhuth DF, Strodthoff D et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 2010; 207: 1081–93.
11. Ketelhuth DF, Tonini GC, Carvalho MD, Ramos RF, Boschcov P, Gidlund M. Autoantibody response to chromatographic fractions from oxidized LDL in unstable angina patients and healthy controls. Scand J Immunol 2008; 68: 456–62.
12. Fredrikson GN, Hedblad B, Berglund G et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 872–8.
13. Assinger A, Wang Y, Butler LM et al. Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) triggers platelet activation and boosts platelet-leukocyte proinflammatory responses. Thromb Haemost 2014; 112: 332–41.
14. Ketelhuth DF, Hansson GK. Cellular immunity, low-density lipoprotein and atherosclerosis: Break of tolerance in the artery wall. Thromb Haemost 2011; 106: 779–86.
15. Holvoet P, Theilmeier G, Shivalkar B, Flameng W, Collen D. LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs. Arterioscler Thromb Vasc Biol 1998; 18: 415–22.
16. Hoff HF, Heideman CL, Jackson RL, Bayardo RJ, Kim HS, Gotto AM Jr. Localization patterns of plasma apolipoproteins in human atherosclerotic lesions. Circ Res 1975; 37: 72–9.
17. Ketelhuth DF, Hansson GK. Modulation of autoimmunity and atherosclerosis - common targets and promising translational approaches against disease. Circ J 2015; 79: 924–33.
18. Hoff HF, O'Neil J, Chisolm GM 3rd et al. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis 1989; 9: 538–49.
19. Aviram M. Low density lipoprotein modification by cholesterol oxidase induces enhanced uptake and cholesterol accumulation in cells. J Biol Chem 1992; 267: 218–25.
20. Zhou X, Robertson AK, Hjerpe C, Hansson GK. Adoptive transfer of CD4 + T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 864–70.
21. Ketelhuth DF, Hansson GK. Adaptive response of T and B Cells in atherosclerosis. Circ Res 2016; 118: 668–78.
22. Linton MF, Farese RVJ, Chiesa G et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein. J Clin Invest 1993; 92: 3029–37.
23. Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest 1998; 101: 1084–93.
24. Folkersen L, van't Hooft F, Chernogubova E et al. Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for cardiovascular disease. Circ Cardiovasc Genet 2010; 3: 365–73.
25. Folkersen L, Persson J, Ekstrand J et al. Prediction of ischemic events on the basis of transcriptomic and genomic profiling in patients undergoing carotid endarterectomy. Mol Med 2012; 18: 669–75.
26. Gistera A, Ketelhuth DF. Immunostaining of lymphocytes in mouse atherosclerotic plaque. Methods Mol Biol 2015; 1339: 149–59.
27. Vita R, Overton JA, Greenbaum JA et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res 2015; 43: D405–12.
28. Wang P, Sidney J, Kim Y et al. Peptide binding predictions for HLA DR. DP and DQ molecules. BMC Bioinformatics 2010; 11: 568.
29. Karosiene E, Rasmussen M, Blicher T, Lund O, Buus S, Nielsen M. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ. Immunogenetics 2013; 65: 711–24.
30. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics 2011; 63: 325–35.
31. Paul S, Lindestam Arlehamn CS, Scriba TJ et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J Immunol Methods 2015; 422: 28–34.
32. Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics 2006; 7: 153.
33. Zhao M, Wigren M, Duner P et al. FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J Immunol 2010; 184: 2253–60.
34. Skalen K, Gustafsson M, Rydberg EK et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750–4.
35. Clark SP, Arden B, Kabelitz D, Mak TW. Comparison of human and mouse T-cell receptor variable gene segment subfamilies. Immunogenetics 1995; 42: 531–40.
36. Ketelhuth DF, Gistera A, Johansson DK, Hansson GK. T cell-based therapies for atherosclerosis. Curr Pharm Des 2013; 19: 5850–8.
37. Paulsson G, Zhou X, Tornquist E, Hansson GK. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 10–7.
38. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 1995; 92: 821–5.
39. Ameli S, Hultgardh-Nilsson A, Regnstrom J et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074–9.
40. George J, Afek A, Gilburd B et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147–52.
41. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 108–14.
42. Schiopu A, Bengtsson J, Soderberg I et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004; 110: 2047–52.
43. Strom A, Fredrikson GN, Schiopu A et al. Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. Atherosclerosis 2007; 190: 298–305.
44. Schiopu A, Frendeus B, Jansson B et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol 2007; 50: 2313–8.
45. Fredrikson GN, Soderberg I, Lindholm M et al. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003; 23: 879–84.
46. Klingenberg R, Lebens M, Hermansson A et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 946–52.
47. Fredrikson GN, Bjorkbacka H, Soderberg I, Ljungcrantz I, Nilsson J. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies. J Intern Med 2008; 264: 563–70.
48. Herbin O, Ait-Oufella H, Yu W et al. Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012; 32: 605–12.
49. Wigren M, Kolbus D, Duner P et al. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J Intern Med 2011; 269: 546–56.
50. van Puijvelde GHM, Hauer AD, de Vos P et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006; 114: 1968–76.
51. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17–24.
52. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752–61.
53. Yip HC, Karulin AY, Tary-Lehmann M et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 1999; 162: 3942–9.
54. Malisan F, Briere F, Bridon JM et al. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J Exp Med 1996; 183: 937–47.
55. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236: 944–7.
56. Binder CJ, Horkko S, Dewan A et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736–43.
57. Habets KL, van Puijvelde GH, van Duivenvoorde LM et al. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc Res 2010; 85: 622–30.
58. Li S, Kievit P, Robertson AK et al. Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. Mol Metab 2013; 2: 256–69.
59. Mendez-Fernandez YV, Stevenson BG, Diehl CJ et al. The inhibitory FcgammaRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-) mice. Atherosclerosis 2011; 214: 73–80.
60. Tse K, Gonen A, Sidney J et al. Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100. Front Immunol 2013; 4: 493.
61. Caligiuri G, Stahl D, Kaveri S et al. Autoreactive antibody repertoire is perturbed in atherosclerotic patients. Lab Invest 2003; 83: 939–47.
62. Sjogren P, Fredrikson GN, Samnegard A et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 2008; 29: 2218–26.
63. Bjorkbacka H, Alm R, Persson M, Hedblad B, Nilsson J, Fredrikson GN. Low levels of apolipoprotein B-100 autoantibodies are associated with increased risk of coronary events. Arterioscler Thromb Vasc Biol 2016; 36: 765–71.